Surface Oncology to Participate in the H.C. Wainwright Global Healthcare Conference
September 11 2020 - 3:00PM
Surface Oncology (Nasdaq:SURF), a clinical-stage
immuno-oncology company developing next-generation immunotherapies
that target the tumor microenvironment, today announced that Jeff
Goater, its chief executive officer, and Robert Ross, M.D., its
chief medical officer, will participate in the upcoming H.C.
Wainwright Global Healthcare Conference held on September 14/15,
2020, discussing Surface Oncology's lead programs, SRF617
(targeting CD39) and SRF388 (targeting IL-27) as well as Surface’s
emerging pre-clinical pipeline, highlighted by SRF813 (targeting
CD112R, aka PVRIG).
About Surface Oncology:
Surface Oncology is an immuno-oncology company developing
next-generation antibody therapies focused on the tumor
microenvironment. Its pipeline includes two wholly-owned lead
programs targeting CD39 (SRF617) and IL-27 (SRF388), a
clinical-stage collaboration with Novartis targeting CD73 (NZV930),
and two preclinical programs, each focused primarily on activating
natural killer cells (via targeting CD112R, also known as PVRIG
(SRF813)) or depleting regulatory T cells (via targeting CCR8
(SRF114)). Surface’s novel cancer immunotherapies are designed to
achieve a clinically meaningful and sustained anti-tumor response
and may be used alone or in combination with other therapies. For
more information, please visit www.surfaceoncology.com.
Contacts:InvestorsMatt
Lanematt@gilmartinir.com617-901-7698
Media Tom Donovan
tom@tenbridgecommunications.com857-559-3397
Surface Oncology (NASDAQ:SURF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Surface Oncology (NASDAQ:SURF)
Historical Stock Chart
From Sep 2023 to Sep 2024